- Home
- FWRG vs COLL Comparison
FWRG vs COLL Comparison
Compare FWRG & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWRG
- COLL
- Stock Information
- Founded
- FWRG 1983
- COLL 2002
- Country
- FWRG United States
- COLL United States
- Employees
- FWRG N/A
- COLL N/A
- Industry
- FWRG Restaurants
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- FWRG Consumer Discretionary
- COLL Health Care
- Exchange
- FWRG Nasdaq
- COLL Nasdaq
- Market Cap
- FWRG 1.1B
- COLL 1.1B
- IPO Year
- FWRG 2021
- COLL 2015
- Fundamental
- Price
- FWRG $17.96
- COLL $45.71
- Analyst Decision
- FWRG Strong Buy
- COLL Strong Buy
- Analyst Count
- FWRG 8
- COLL 5
- Target Price
- FWRG $21.88
- COLL $45.40
- AVG Volume (30 Days)
- FWRG 1.4M
- COLL 549.9K
- Earning Date
- FWRG 11-04-2025
- COLL 11-06-2025
- Dividend Yield
- FWRG N/A
- COLL N/A
- EPS Growth
- FWRG N/A
- COLL N/A
- EPS
- FWRG 0.08
- COLL 1.63
- Revenue
- FWRG $1,169,440,000.00
- COLL $757,067,000.00
- Revenue This Year
- FWRG $22.25
- COLL $21.41
- Revenue Next Year
- FWRG $16.18
- COLL $3.28
- P/E Ratio
- FWRG $224.10
- COLL $28.10
- Revenue Growth
- FWRG 17.27
- COLL 26.34
- 52 Week Low
- FWRG $12.90
- COLL $23.23
- 52 Week High
- FWRG $22.71
- COLL $48.18
- Technical
- Relative Strength Index (RSI)
- FWRG 57.42
- COLL 70.64
- Support Level
- FWRG $15.21
- COLL $43.12
- Resistance Level
- FWRG $17.86
- COLL $46.48
- Average True Range (ATR)
- FWRG 0.93
- COLL 1.83
- MACD
- FWRG 0.02
- COLL 0.04
- Stochastic Oscillator
- FWRG 76.79
- COLL 71.98
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.